Eli Lilly Price to Free Cash Flow Ratio 2010-2024 | LLY

Historical price to free cash flow ratio values for Eli Lilly (LLY) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-05-21 803.17 0.00
2024-03-31 776.68 $-0.10 0.00
2023-12-31 580.96 $0.88 662.14
2023-09-30 534.34 $3.70 144.53
2023-06-30 465.56 $4.11 113.41
2023-03-31 340.03 $5.13 66.27
2022-12-31 361.06 $6.34 56.99
2022-09-30 318.25 $7.21 44.12
2022-06-30 318.10 $6.87 46.33
2022-03-31 280.02 $7.49 37.38
2021-12-31 268.97 $6.64 40.49
2021-09-30 224.25 $5.97 37.55
2021-06-30 222.05 $6.10 36.39
2021-03-31 179.95 $7.00 25.72
2020-12-31 161.96 $5.60 28.91
2020-09-30 141.24 $5.82 24.26
2020-06-30 155.90 $5.64 27.66
2020-03-31 131.11 $4.09 32.05
2019-12-31 123.57 $4.06 30.41
2019-09-30 104.54 $3.36 31.16
2019-06-30 103.57 $3.80 27.25
2019-03-31 120.63 $4.09 29.48
2018-12-31 107.01 $4.17 25.64
2018-09-30 98.73 $4.42 22.32
2018-06-30 78.08 $4.17 18.74
2018-03-31 70.31 $4.34 16.19
2017-12-31 76.19 $4.31 17.66
2017-09-30 76.68 $4.64 16.53
2017-06-30 73.31 $4.44 16.52
2017-03-31 74.44 $4.17 17.83
2016-12-31 64.66 $3.66 17.66
2016-09-30 70.10 $2.75 25.45
2016-06-30 68.35 $2.18 31.31
2016-03-31 62.09 $1.77 35.01
2015-12-31 72.15 $1.87 38.62
2015-09-30 71.21 $2.18 32.68
2015-06-30 70.62 $2.70 26.17
2015-03-31 61.03 $2.76 22.11
2014-12-31 57.55 $3.08 18.67
2014-09-30 53.70 $3.43 15.64
2014-06-30 51.07 $3.74 13.66
2014-03-31 47.96 $4.38 10.95
2013-12-31 41.18 $4.52 9.11
2013-09-30 40.25 $4.28 9.40
2013-06-30 38.93 $3.89 10.00
2013-03-31 44.62 $3.51 12.71
2012-12-31 38.40 $3.96 9.70
2012-09-30 36.53 $4.41 8.29
2012-06-30 32.69 $4.89 6.68
2012-03-31 30.31 $5.60 5.42
2011-12-31 30.90 $5.91 5.23
2011-09-30 27.13 $6.18 4.39
2011-06-30 27.16 $5.92 4.59
2011-03-31 25.13 $5.81 4.33
2010-12-31 24.69 $5.60 4.41
2010-09-30 25.39 $5.41 4.70
2010-06-30 22.97 $5.00 4.60
2010-03-31 24.49 $4.09 6.00
2009-12-31 23.81 $3.27 7.29
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $763.337B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $606.535B 46.61
Johnson & Johnson (JNJ) United States $363.986B 14.46
Merck (MRK) United States $331.190B 60.26
AbbVie (ABBV) United States $287.713B 14.87
AstraZeneca (AZN) United Kingdom $245.493B 21.34
Novartis AG (NVS) Switzerland $210.205B 14.90
Pfizer (PFE) United States $161.838B 20.11
Sanofi (SNY) $123.824B 11.68
Innoviva (INVA) United States $1.008B 7.08